139 related articles for article (PubMed ID: 36808592)
1. ASO Author Reflections: Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving Versus Non-minority-Serving Hospitals.
Lima HA; Moazzam Z; Pawlik TM
Ann Surg Oncol; 2023 Jul; 30(7):4373-4374. PubMed ID: 36808592
[No Abstract] [Full Text] [Related]
2. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals.
Elshami M; Hoehn RS; Ammori JB; Hardacre JM; Selfridge JE; Bajor D; Mohamed A; Chakrabarti S; Mahipal A; Winter JM; Ocuin LM
HPB (Oxford); 2023 Dec; 25(12):1502-1512. PubMed ID: 37558565
[TBL] [Abstract][Full Text] [Related]
3. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals.
Lima HA; Alaimo L; Moazzam Z; Endo Y; Woldesenbet S; Katayama E; Munir MM; Shaikh C; Ruff SM; Dillhoff M; Beane J; Cloyd J; Ejaz A; Resende V; Pawlik TM
Ann Surg Oncol; 2023 Jul; 30(7):4363-4372. PubMed ID: 36800128
[TBL] [Abstract][Full Text] [Related]
4. Disparities in NCCN Guideline Compliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals.
Tsilimigras DI; Dalmacy D; Hyer JM; Diaz A; Abbas A; Pawlik TM
Ann Surg Oncol; 2021 Dec; 28(13):8162-8171. PubMed ID: 34036428
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Minority-Serving Hospitals are Associated with Lower Likelihood of Providing NCCN Guideline Compliant Care to Patients with Resectable Cholangiocarcinoma.
Tsilimigras DI; Pawlik TM
Ann Surg Oncol; 2021 Dec; 28(13):8172-8173. PubMed ID: 34018087
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.
Chattopadhyay A; Wu CH; Tien YW; Lu TP
Ann Surg Oncol; 2022 Mar; 29(3):1616-1617. PubMed ID: 34802101
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Real Prevalence of Occult Cancer Cells in Peritoneal Lavage in Patients with Pancreatic Ductal Adenocarcinoma.
Suenaga M; Fujii T
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):893-894. PubMed ID: 32812111
[No Abstract] [Full Text] [Related]
8. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
9. ASO Author Reflections: County-Level Social Vulnerability Associated with Disparities in Pancreatic Cancer Treatment, Especially among Patients from Racial and Ethnic Minorities.
Diaz A; Azap RA; Pawlik TM
Ann Surg Oncol; 2021 Oct; 28(11):6317-6318. PubMed ID: 33811306
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Unlocking the Value of Inpatient Palliative Care for Patients with Pancreatic Cancer.
Kim S; Chervu N; Premji A; Mallick S; Verma A; Ali K; Benharash P; Donahue T
Ann Surg Oncol; 2024 Feb; 31(2):1362-1363. PubMed ID: 38063981
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
Jin W; Xu HX; Yu XJ; Liu L
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Frailty in Pancreatic Cancers.
Zhang F; Yan Y; Ge C
Ann Surg Oncol; 2024 Jan; 31(1):545. PubMed ID: 37843665
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma.
Kubota K; Shimizu A; Soejima Y
Ann Surg Oncol; 2022 Feb; 29(2):1449-1450. PubMed ID: 34618246
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
Groot VP; Wolfgang CL; He J
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: Health Disparities in Pancreatic Cancer.
Lutfi W; Hogg ME
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):824-825. PubMed ID: 30377920
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic Carcinoma: An International Delphi Survey.
Pessaux P; Cherkaoui Z
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):773-774. PubMed ID: 32495283
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma.
Tamburrino D; Guarneri G; Capurso G; Falconi M
Ann Surg Oncol; 2021 Apr; 28(4):2323-2324. PubMed ID: 32929602
[No Abstract] [Full Text] [Related]
19. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.
Visser BC; Ma Y; Zak Y; Poultsides GA; Norton JA; Rhoads KF
HPB (Oxford); 2012 Aug; 14(8):539-47. PubMed ID: 22762402
[TBL] [Abstract][Full Text] [Related]
20. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma.
Newhook TE; Tzeng CD
Ann Surg Oncol; 2021 Mar; 28(3):1570-1571. PubMed ID: 32880772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
